Unifying clinical trial data for a UK life sciences group

Context and constraints

Clinical trial data management sits under a set of constraints most enterprise data programmes never have to weigh together at once. The data itself is high-stakes, feeding directly into decisions about patient safety and, eventually, into regulatory submissions that determine whether a treatment reaches patients at all. The provenance of every data point matters as much as its value, because a regulator reviewing a submission needs to trust not just the numbers but the complete, demonstrable chain of custody behind them. And the environment producing that data is inherently fragmented by design: trials are run through contract research organisations chosen per study, using electronic data capture systems chosen per CRO, feeding into lab networks that vary by site and by test type. No single vendor or standard governs the whole pipeline, which means the reconciliation problem is structural, not a symptom of poor tooling choices by any one team.

The client's clinical data management function had absorbed that structural fragmentation by building an impressive amount of manual process around it: detailed reconciliation checklists, cross-referencing spreadsheets maintained per trial, and a genuine depth of institutional knowledge about which CRO tended to format lab units differently or which site historically had transcription issues on case report forms. That knowledge was valuable, but it lived in people rather than in a system, which created real fragility. A departing team member took months of hard-won reconciliation pattern recognition with them, and demonstrating audit readiness to a regulator meant asking someone to manually reconstruct a data lineage story that a well-designed system should have been able to produce on demand.

Building for validation from day one, not as an afterthought

Unlike a typical enterprise data platform build, this engagement required computerised systems validation as a first-class deliverable rather than a compliance checkbox added at the end. We structured the entire build around the client's existing validation framework from the outset: every ingestion rule, transformation step and access control was specified, documented and tested against a formal requirements traceability matrix before it went anywhere near live trial data. This slowed the early phases of the build relative to how we might normally sequence a data platform engagement, and that trade-off was deliberate and correct. A platform handling clinical trial data that cannot demonstrate, on audit, exactly what it does and why, is not a usable platform in this domain regardless of its technical sophistication.

The validation discipline extended to how we handled changes after go-live. Every subsequent modification to an ingestion rule or transformation, however minor, went through the same change control and revalidation process used for the original build, with the rationale and approval captured in the same audit trail as the data itself. This felt, at times, like unnecessary overhead for genuinely small changes, and we heard that view from engineers on the programme more than once. It is the correct discipline nonetheless: a validated system that quietly drifts out of its validated state through undocumented small changes is, from a regulatory audit perspective, no longer a validated system at all.

Designing the ingestion and reconciliation layer

The core technical problem was building an ingestion layer flexible enough to accept data from any CRO or EDC system without a bespoke integration for every new trial relationship, while still enforcing consistent, auditable data quality rules at the point of entry. We built a configurable mapping layer that let clinical data management staff define new source formats through structured configuration rather than requiring an engineering change for every new CRO relationship, a deliberate choice to put the client's own domain experts in control of onboarding rather than making them dependent on us for every new trial. Validation rules ran at ingestion, flagging out-of-range values, unit mismatches, and cross-source discrepancies for review before data ever reached the canonical repository, rather than allowing inconsistencies to surface downstream where they were harder and more expensive to trace back to source.

Reconciliation logic paid particular attention to the class of discrepancy the client's team had told us, during discovery, caused the most wasted effort: the same clinical event reported slightly differently by the site's case report form and by the central lab feed, neither one simply wrong, but requiring a domain judgement call to resolve. We built the platform to surface these for structured human review with both source values and full context displayed side by side, rather than attempting to auto-resolve judgement calls that genuinely required a clinician's or data manager's expertise. That distinction, between automating mechanical reconciliation and preserving human judgement for genuine ambiguity, was one the client's quality team was firm about throughout, and it shaped nearly every design decision in the reconciliation layer.

CDISC alignment and the statistical programming handoff

Transforming reconciled source data into CDISC SDTM domains and, from there, into ADaM analysis datasets, had previously been bespoke mapping work repeated for every trial, done largely by hand by statistical programmers under submission deadline pressure. We built a repeatable transformation pipeline aligned to the client's standard SDTM implementation guide conventions, configurable per trial for genuine protocol-specific differences but consistent in its core logic, so that the bulk of the mapping work no longer had to be reinvented for each new study. Statistical programmers remained firmly in control of the analysis layer, but the volume of mechanical mapping work they had to do before analysis could begin dropped substantially, and the team told us during rollout that the time saved was consistently redirected into more thorough analysis review rather than simply absorbed as slack.

We integrated the platform directly with the client's existing statistical programming environment rather than asking programmers to adopt a new toolchain, recognising that the platform's value depended on fitting into an established, validated way of working rather than displacing it. Programmers could pull a validated, versioned dataset directly into their existing tools, with full lineage back to source data available without leaving that environment, which meant adoption did not require a parallel change management effort on top of the platform build itself.

Lessons learned

The clearest lesson from this engagement was that treating validation and audit trail requirements as core design constraints from the first architecture decision, rather than retrofitting them once a platform's functional shape had already been decided, saved substantial rework later and produced a materially more trustworthy system. Teams tempted to build the functional pipeline first and add compliance controls afterward in a domain like this one are taking on real risk, since some of the most important compliance requirements, like complete lineage capture at every transformation step, are difficult to bolt on cleanly after the fact.

The second lesson was about where to automate and where deliberately not to. The reconciliation layer's value came as much from what it refused to auto-resolve, genuine clinical judgement calls, as from what it did automate, mechanical format and consistency checking. Getting that boundary right required close, ongoing collaboration with the client's clinical data management and quality teams throughout the build, not just at requirements gathering, and it is a discipline we now apply deliberately on any engagement touching regulated, high-stakes data.

Finally, putting configuration of new data sources into the hands of the client's own domain experts, rather than keeping that capability locked inside our delivery team, has paid off well beyond the engagement's formal end. The client has onboarded further CRO relationships onto the platform independently since go-live, without needing to re-engage us for each one, which is precisely the outcome a platform investment in this domain should produce.

If you are managing clinical trial, regulatory or other high-stakes data across a fragmented set of external partners and want a platform built for genuine audit readiness rather than compliance in name only, we would be glad to discuss what a programme like this might look like for your organisation. Email sales@halfteck.com.